Clinical trials: Poor Graft Function
Poor Graft Function
Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function
The purpose of this study was to evaluate the efficacy of eltrombopag for poor graft function (PGF) on overall hematologic response (partial and complete), as determined by platelet, hemoglobin and neutrophil counts by 16 weeks…
- Trial name
- ELTION (NCT03718533)
- Testing
- Eltrombopag
- Where
- 7 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Poor Graft Function, Myelodysplastic Syndromes
Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCT
Preclinical evidence indicates that IL-1 inflammatory signaling suppresses bone marrow mesenchymal stromal cells (MSCs) from secreting stem cell factor (SCF), leading to failure of their hematopoietic supportive capacity, and…
- Conditions
- Poor Graft Function, Myelodysplastic Syndromes, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT07888348
- Testing
- Anakinra
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Ruijin Hospital
Poor Graft Function
The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation
This study is conducted in a prospective, single-center clinical design and is divided into two stages: dose escalation and dose extension.
- Trial name
- NCT06792682
- Testing
- Dose escalation, Dose extension
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China